secwatch.observer — SEC 8-K summary
======================================

Issuer:     biote Corp. (BTMD)
CIK:        0001819253
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-104014
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biote Q2 rev $48.9M, net income $3.9M vs year-ago loss; Adj. EBITDA up 19%
--------------------------------------------------------------------------

- Revenue $48.9M, gross margin 71.6%; net income $3.9M ($0.10 diluted EPS) vs net loss $10.4M ($0.21 loss) in Q2 2024.
- Adjusted EBITDA $15.2M (margin 31.1%), up 19.1% YoY; benefit from Q3 shift of annual marketing event and 503B vertical integration.
- CEO announced organizational restructuring in early May to accelerate new provider and clinic growth; new leadership and upgraded sales compensation.
- Q2 revenue decreased slightly YoY, but profitability and margins expanded significantly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819253/000095017025104014/0000950170-25-104014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819253/000095017025104014/btmd-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer